1207754-99-1

Basic information

• Product Name: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate
• Synonyms: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate;tert-butyl (2R)-2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate;(2R)-1-Boc-2-methylpyrrolidine-2-methanol
• CAS NO: 1207754-99-1
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• Mol File: 1207754-99-1.mol

Chemical Properties

• Boiling Point: 293.8±13.0 °C(Predicted)
• Appearance: /
• Density: 1.055±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate(1207754-99-1)
• EPA Substance Registry System: (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate(1207754-99-1)

Safety Data

• Hazardous Substances Data: 1207754-99-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate is used as a chiral building block for the synthesis of various pharmaceutical compounds due to its unique configuration and functional groups. Its chirality and specific substituents may contribute to the development of enantioselective drugs with improved efficacy and reduced side effects.
Used in Medicinal Chemistry Research:
(R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate serves as a valuable intermediate in the synthesis of biologically active molecules and potential drug candidates. Its unique structural features and stability make it a promising candidate for further exploration in medicinal chemistry research.
Used in Chemical Synthesis:
(R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate is used as a versatile synthetic intermediate in the preparation of various organic compounds, including chiral ligands, catalysts, and other specialty chemicals. Its functional groups and chiral center provide opportunities for further chemical transformations and applications in diverse chemical processes.
Note: The specific applications and uses of (R)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate may vary depending on the industry and the desired outcome. The potential uses mentioned above are based on the general properties and characteristics of the compound, and further research and experimentation may be required to fully explore its potential applications.

Upstream product

• 619307-07-2 (R)-N-(tert-butoxycarbonyl)-α-methylproline ethyl ester 
• 166170-15-6 (R)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid 
• 63399-77-9 (R)-2-Methyl-1-azacyclopentan-2-carbonsaeure 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1207755-00-7 1,1-dimethylethyl (2R)-2-methyl-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)pyrrolidine-1-carboxylate 
• 1407975-85-2 C₂₁H₂₈F₃NO₅ 
• 1407975-86-3 C₅₆H₇₉N₅O₇ 

Relevant articles and documents

ALKYNYL QUINAZOLINE COMPOUNDS

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

Benzimidazole-2-piperazine compound, its pharmaceutical composition and its preparation and use

The invention relates to a benzimidazole-2-piperazine derivative and a preparing method and application of the benzimidazole-2-piperazine derivative in medicine, in particular to a novel benzimidazole-2-piperazine derivative shown in the general formula (I), a preparing method of the derivative, a pharmaceutical composition containing the derivative and application of the derivative serving as a therapeutic agent, especially serving as a poly (ADP-ribose) polymerase (PARP) inhibitor. In the general formula (I), R refers to hydrogen or halogen, G refers to carbonyl or methylene, m is 1-2, n is 1-3, and Q refers to hydrogen or C1-C4 alkyl. When X is methylene and Y is NR1 or methylene, X is NR1; R1 refers to hydrogen, C1-C6 alkyl, benzyl, COR2 or SO2R2; R2 refers to the following groups which are not substituted or groups substituted by 1-3 substituent groups, including C1-C6 alkyl, C3-C8 naphthenic base, phenyl, benzyl, naphthyl and C5-C10 aromatic heterocycle base, heterocycle in the C5-C10 aromatic heterocycle base comprises 1-3 heteroatoms selected from N, O and S, and the substituent groups are selected from the following atoms or groups of C1-C6 alkyl, C1-C6 alkoxy, halogen, amidogen, nitryl, sulfydryl, hydroxyl, cyanogroup and trifluoromethyl. The general formula (I) is shown in the specification.

Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase

Orally bioavailable inhibitors of β-(1,3)-d-glucan synthase have been pursued as new, broad-spectrum fungicidal therapies suitable for treatment in immunocompromised patients. Toward this end, a collaborative medicinal chemistry program was established based on semisynthetic derivatization of the triterpenoid glycoside natural product enfumafungin in order to optimize in vivo antifungal activity and oral absorption properties. In the course of these studies, it was hypothesized that the pharmacokinetic properties of the semisynthetic enfumafungin analog 3 could be improved by tethering the alkyl groups proximal to the basic nitrogen of the C3-aminoether side chain into an azacyclic system, so as to preclude oxidative N-demethylation. The results of this research effort are disclosed herein.

ANTIFUNGAL AGENTS

Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs,,as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

ANTIFUNGAL AGENTS

Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.